Cardiac conversion

Tenaya’s gene therapies aim to reverse heart failure by restoring heart muscle

Cell therapies that aim to reverse disease progression in heart failure and myocardial infarction by restoring cardiomyocytes are beginning to report positive clinical data, but they require frequent administration via invasive procedures. Tenaya Therapeutics Inc. is developing gene therapies combined with small molecules that convert cardiac fibroblasts into heart muscle cells in vivo, which could be a more efficient approach.

Marketed therapies for cardiovascular disease work by reducing stress on the existing heart muscle.

Read the full 731 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE